<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Fluvastatin: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Fluvastatin: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Fluvastatin: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="8473" href="/d/html/8473.html" rel="external">see "Fluvastatin: Drug information"</a> and <a class="drug drug_patient" data-topicid="12494" href="/d/html/12494.html" rel="external">see "Fluvastatin: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block spa drugH1Div" id="F55989379"><span class="drugH1">Special Alerts</span>
<div class="collapsible">
<span class="collapsible-title">Statin Pregnancy Contraindication Update</span>
<span class="collapsible-date">July 2021</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">After a comprehensive review of all available data, the FDA is requesting all statin manufacturers to remove the contraindication in the prescribing information against using statins in pregnant patients. Although statin therapy should be discontinued in most pregnant patients, health care providers should consider the ongoing therapeutic needs of the individual patient, especially patients at very high risk of cardiovascular events during pregnancy, such as patients with homozygous familial hypercholesterolemia or those with established cardiovascular disease. Additionally, breastfeeding is still not recommended in patients taking a statin; health care providers should determine whether it is better to temporarily stop statin therapy while breastfeeding or to continue statin therapy and not have the patient breastfeed. If ongoing statin treatment is necessary, infant formula and other alternatives are available. The FDA expects that removing the contraindication will enable health care providers and patients to make individual decisions about benefit and risk, especially for those at very high risk of heart attack or stroke.</p>
<p style="text-indent:0em;">Further information is available at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fdrug-safety-and-availability%2Ffda-requests-removal-strongest-warning-against-using-cholesterol-lowering-statins-during-pregnancy&amp;token=gxfbJKP%2B4jbjRRe1dXCv59qhZFmTmV73qmf%2FX%2BpwMjvINmMExoP9r7EcTZq6LKtsQ%2FwwXarvQCVId0NgjG9XzdICKlsdFJ73s%2FDoyuycmVDaUZCyqN73GrYM2%2BxRAta2zcZQxGheSuTnwZzuZPE4Up8XPwPhb7srLeP9xEjjtcA%3D&amp;TOPIC_ID=13044" target="_blank">https://www.fda.gov/drugs/drug-safety-and-availability/fda-requests-removal-strongest-warning-against-using-cholesterol-lowering-statins-during-pregnancy</a>.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F173506"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Lescol XL</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866956"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Lescol XL [DSC];</li>
<li>TEVA-Fluvastatin</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1014860"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antilipemic Agent</span>;</li>
<li>
<span class="list-set-name">HMG-CoA Reductase Inhibitor</span></li></ul></div>
<div class="block dop drugH1Div" id="F2931789"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8dbf85b0-0aad-4091-93c4-4fe47f31e396">Hyperlipidemia or heterozygous familial and nonfamilial hypercholesterolemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperlipidemia or heterozygous familial and nonfamilial hypercholesterolemia: Note:</b> Begin treatment if after adequate trial of diet the following are present: LDL-C ≥190 mg/dL or LDL-C remains ≥160 mg/dL and positive family history of premature cardiovascular disease or meets NCEP classification (NHLBI 2011). Therapy may be considered for children 8-9 years of age meeting the above criteria or for children with diabetes mellitus and LDL-C ≥130 mg/dL (Daniels 2008).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥10 years and Adolescents ≤16 years (female patients should be ≥1 year postmenarche): Oral:</p>
<p style="text-indent:-2em;margin-left:6em;">Immediate release capsule: Initial: 20 mg once daily; may titrate dose or frequency (twice daily dosing) at 6-week intervals; maximum dose: 40 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:6em;">Extended release tablet: Should not be used to initiate therapy; may convert patient if total daily dose is 80 mg/day.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosing adjustment for toxicity: Muscle symptoms (potential myopathy):</b> Children ≥10 years and Adolescents: Discontinue use until symptoms can be evaluated; check creatine phosphokinase (CPK) level; based on experience in adult patients, also evaluate patient for conditions that may increase the risk for muscle symptoms (eg, hypothyroidism, reduced renal or hepatic function, rheumatologic disorders such as polymyalgia rheumatica, steroid myopathy, vitamin D deficiency, or primary muscle diseases). Upon resolution (symptoms and any associated CPK abnormalities), resume the original or consider a lower dose of fluvastatin and retitrate. If muscle symptoms recur, discontinue fluvastatin use. After muscle symptom resolution, may then reinitiate a different statin at an initial low dose; gradually increase if tolerated. Based on experience in adult patients, if muscle symptoms or elevated CPK persists for 2 months in the absence of continued statin use, consider other causes of muscle symptoms. If determined to be due to another condition aside from statin use, may resume statin therapy at the original dose (NHLBI 2011; Stone 2013).</p></div>
<div class="block dorp drugH1Div" id="F51263890"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no pediatric specific recommendations; based on experience in adult patients, no adjustment may be necessary with mild to moderate impairment. With severe renal impairment, use with caution, particularly when using maximum doses (has not been studied).</p></div>
<div class="block dohp drugH1Div" id="F51112190"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">All patients: There are no dosage adjustments provided in the manufacturer's labeling; systemic exposure may be increased in patients with liver disease; use is contraindicated in patients with active liver disease or unexplained transaminase elevations.</p></div>
<div class="block doa drugH1Div" id="F173511"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="8473" href="/d/html/8473.html" rel="external">see "Fluvastatin: Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> Fluvastatin 80 mg/day is considered a moderate-intensity statin (generally reduces LDL-C by ~30% to 49%). Fluvastatin 20 to 40 mg/day is considered a low-intensity statin (reduces LDL-C &lt;30%). If LDL-C must be lowered ≥50%, select an alternative high-intensity statin (atorvastatin or rosuvastatin). Assess response ~1 to 3 months after initiation of therapy or dose adjustment and every 3 to 12 months thereafter (ACC/AHA [Grundy 2019]).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations:</b> Use in conjunction with lifestyle modification (eg, diet, exercise). When initiating therapy and selecting dose intensity, consider age, baseline low-density lipoprotein cholesterol (LDL-C), 10-year atherosclerotic cardiovascular disease (ASCVD) risk, risk-enhancing factors, potential adverse effects, and drug interactions (ACC/AHA [Grundy 2019]).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="355cd99a-0024-4930-8b95-6aee3ac5d71d">Heterozygous familial hypercholesterolemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Heterozygous familial hypercholesterolemia (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Use of fluvastatin should be limited to patients unable to tolerate a high-intensity statin. Multiple lipid-lowering therapies may be needed if statin monotherapy is not effective. Referral to a lipid specialist should be considered if treatment goals are not met (ACC/AHA [Grundy 2019]).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Patients unable to tolerate high-intensity therapy (eg, appropriate dose of atorvastatin or rosuvastatin):</b></i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Moderate-intensity therapy: Oral: </b></p>
<p style="text-indent:-2em;margin-left:8em;">Immediate release: 40 mg twice daily (ACC/AHA [Grundy 2019]).</p>
<p style="text-indent:-2em;margin-left:8em;">Extended release: 80 mg once daily (ACC/AHA [Grundy 2019]).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="be04224c-8e9d-4248-8315-86a413718095">Homozygous familial hypercholesterolemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Homozygous familial hypercholesterolemia (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Use of fluvastatin should be limited to patients unable to tolerate a high-intensity statin. Multiple lipid-lowering therapies may be needed if statin monotherapy is not effective. Referral to a lipid specialist should be considered if treatment goals are not met (ACC/AHA [Grundy 2019]).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Patients unable to tolerate high-intensity therapy (eg, appropriate dose of atorvastatin or rosuvastatin):</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Moderate-intensity therapy: Oral:</b></p>
<p style="text-indent:-2em;margin-left:8em;">Immediate release: 40 mg twice daily (ACC/AHA [Grundy 2019]).</p>
<p style="text-indent:-2em;margin-left:8em;">Extended release: 80 mg once daily (ACC/AHA [Grundy 2019]).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b4d76cb4-430b-418c-bf7b-688e7bf30bd0">Prevention of atherosclerotic cardiovascular disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Prevention of atherosclerotic cardiovascular disease:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> If LDL-C goal (eg, percent reduction or absolute goal) is not met with the initial dose, may consider switching to a high-intensity statin (atorvastatin or rosuvastatin) based on estimated 10-year atherosclerotic cardiovascular disease (ASCVD) risk (see ACC/AHA ASCVD Risk Estimator Plus online), LDL-C response, and tolerability. Additional lipid-lowering therapy may be warranted (ACC/AHA [Grundy 2019]).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Primary prevention:</b></i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Patients <i>without</i> diabetes, 40 to 75 years of age, and LDL-C 70 to 189 mg/dL:</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>
<i>ASCVD 10-year risk 5% to &lt;7.5%:</i></b></p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Note: </b>Depending on baseline LDL-C and presence of risk-enhancing factors, consider statin therapy after shared decision-making with patient. Some experts suggest shared decision-making if ASCVD 10-year risk is 5% to 10%; however, in patients with a baseline LDL-C ≥160 mg/dL, statin therapy is usually recommended (Pignone 2022).</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Moderate-intensity therapy: Oral:</b></p>
<p style="text-indent:-2em;margin-left:12em;">Immediate release: 40 mg twice daily to reduce LDL-C by ~30% to 49% (ACC/AHA [Grundy 2019]).</p>
<p style="text-indent:-2em;margin-left:12em;">Extended release: 80 mg once daily to reduce LDL-C by ~30% to 49% (ACC/AHA [Grundy 2019]).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>
<i>ASCVD 10-year risk ≥7.5% to &lt;20%:</i></b></p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Note:</b> Depending on baseline LDL-C and presence of risk-enhancing factors, consider statin therapy after shared decision-making with patient. Some experts suggest initiating moderate-intensity statin therapy in most patients if ASCVD 10-year risk is &gt;10% to &lt;20% and LDL-C is &gt;100 mg/dL (Pignone 2022). <b></b></p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Moderate-intensity therapy: Oral:</b></p>
<p style="text-indent:-2em;margin-left:12em;">Immediate release: 40 mg twice daily to reduce LDL-C by ~30% to 49% (ACC/AHA [Grundy 2019]).</p>
<p style="text-indent:-2em;margin-left:12em;">Extended release: 80 mg once daily to reduce LDL-C by ~30% to 49% (ACC/AHA [Grundy 2019]).</p>
<p style="text-indent:-2em;margin-left:12em;">
<b>Note:</b> Higher-risk patients with multiple risk-enhancing factors may benefit from a high-intensity statin therapy (ie, with atorvastatin or rosuvastatin) to reduce LDL-C by ≥50% (ACC/AHA [Grundy 2019]).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>
<i>ASCVD 10-year risk ≥20% (alternative agent):</i></b></p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Note: </b>Use of fluvastatin should be limited to patients unable to tolerate high-intensity statin (ACC/AHA [Grundy 2019]).</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>
<i>Patients unable to tolerate high-intensity therapy (eg, appropriate dose of atorvastatin or rosuvastatin):</i></b></p>
<p style="text-indent:-2em;margin-left:12em;">
<b>Moderate-intensity therapy: Oral:</b></p>
<p style="text-indent:-2em;margin-left:14em;">Immediate release: 40 mg twice daily (ACC/AHA [Grundy 2019]).</p>
<p style="text-indent:-2em;margin-left:14em;">Extended release: 80 mg once daily (ACC/AHA [Grundy 2019]).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Patients <i>with</i> diabetes:</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>
<i>40 to 75 years of age without additional ASCVD risk factors:</i></b></p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Moderate-intensity therapy: Oral:</b></p>
<p style="text-indent:-2em;margin-left:12em;">Immediate release: 40 mg twice daily to reduce LDL-C by ~30% to 49% (ACC/AHA [Grundy 2019]).</p>
<p style="text-indent:-2em;margin-left:12em;">Extended release: 80 mg once daily to reduce LDL-C by ~30% to 49% (ACC/AHA [Grundy 2019]).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>
<i>ASCVD 10-year risk ≥7.5% or multiple ASCVD risk factors (alternative agent)</i></b>
<i>:</i></p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Note: </b>Use of fluvastatin should be limited to patients unable to tolerate high-intensity statin (ACC/AHA [Grundy 2019]; ACC [Lloyd-Jones 2022]).</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>
<i>Patients unable to tolerate high-intensity therapy (eg, appropriate dose of atorvastatin or rosuvastatin):</i></b></p>
<p style="text-indent:-2em;margin-left:12em;">
<b>Moderate-intensity therapy: Oral:</b></p>
<p style="text-indent:-2em;margin-left:14em;">Immediate release: 40 mg twice daily (ACC/AHA [Grundy 2019]).</p>
<p style="text-indent:-2em;margin-left:14em;">Extended release: 80 mg once daily (ACC/AHA [Grundy 2019]).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Patients with LDL-C ≥190 mg/dL and 20 to 75 years of age (regardless of ASCVD risk estimate or coexisting diabetes mellitus) (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note: </b>Use of fluvastatin should be limited to patients unable to tolerate high-intensity statin (ACC/AHA [Grundy 2019]).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>
<i>Patients unable to tolerate high-intensity therapy (eg, appropriate dose of atorvastatin or rosuvastatin):</i></b></p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Moderate-intensity therapy: Oral:</b></p>
<p style="text-indent:-2em;margin-left:12em;">Immediate release: 40 mg twice daily (ACC/AHA [Grundy 2019]).</p>
<p style="text-indent:-2em;margin-left:12em;">Extended release: 80 mg once daily (ACC/AHA [Grundy 2019]).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Secondary prevention in patients with established ASCVD (eg, coronary heart disease, cerebrovascular disease [ischemic stroke or transient ischemic attack], peripheral arterial disease) (alternative agent):</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Use of fluvastatin should be limited to patients unable to tolerate a high-intensity statin. Patients with high-risk ASCVD may require additional therapies to achieve LDL-C goal (eg, &lt;70 mg/dL or &lt;50 mg/dL if very high risk) (ACC/AHA [Grundy 2019]; Rosenson 2020).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Patients unable to tolerate high-intensity therapy (eg, appropriate dose of atorvastatin or rosuvastatin):</i></b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Moderate-intensity therapy: Oral:</b></p>
<p style="text-indent:-2em;margin-left:10em;">Immediate release: 40 mg twice daily (ACC/AHA [Grundy 2019]).</p>
<p style="text-indent:-2em;margin-left:10em;">Extended release: 80 mg once daily (ACC/AHA [Grundy 2019]).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991817"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild to moderate impairment: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment: There are no dosage adjustments provided in the manufacturer's labeling; use with caution, particularly at doses &gt;40 mg/day (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F50989096"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">Use is contraindicated in patients with active acute liver failure, unexplained persistent transaminase elevations, or decompensated cirrhosis.</p></div>
<div class="block adr drugH1Div" id="F173472"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (5%, including upper abdominal pain), diarrhea (5%), dyspepsia (8%), nausea (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary tract infection (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum transaminases (≤5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Fatigue (3%), headache (9%), insomnia (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthropathy (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchitis (2% to 3%), flu-like symptoms (7%), sinusitis (3% to 4%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Neuromuscular &amp; skeletal: Increased creatine phosphokinase in blood specimen (&gt;10 × normal), myopathy</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Cardiovascular: Chest pain</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia, dermatitis (including bullous dermatitis), eczema, lichen planus, pruritus, skin changes (including changes in nails, changes of hair, cutaneous nodule, dry mucous membranes, nodule, skin discoloration, xeroderma), skin rash</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased libido, elevated glycosylated hemoglobin, gynecomastia, increase in fasting plasma glucose, thyroid dysfunction</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Anorexia, dysgeusia, pancreatitis (Tysk 2002), vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Cystitis (interstitial) (Huang 2015), erectile dysfunction</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Cholestatic jaundice, fulminant hepatic necrosis, hepatic cirrhosis, hepatic failure, hepatic neoplasm, hepatitis, hyperbilirubinemia, increased gamma-glutamyl transferase, increased serum alkaline phosphatase, liver steatosis</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (including anaphylaxis, angioedema)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anxiety, cranial nerve disorder (including facial paresis, impairment of extraocular movement), depression, dysesthesia, hypoesthesia, myasthenia, paresthesia, peripheral nerve palsy, peripheral neuropathy, psychic disorder, tremor, vertigo</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia, muscle cramps, muscle spasm, myoglobinuria, myositis (Alanazi 2021), rhabdomyolysis (Baek 2011)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Ophthalmoplegia, progression of cataract</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Interstitial lung disease</p></div>
<div class="block coi drugH1Div" id="F173487"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity (anaphylaxis, angioedema, and Stevens-Johnson syndrome) to fluvastatin or any component of the formulation; acute liver failure or decompensated cirrhosis.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Unexplained persistent elevated transaminases; breastfeeding; pregnancy.</p></div>
<div class="block war drugH1Div" id="F173469"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Diabetes mellitus: Increases in HbA<sub>1c</sub> and fasting blood glucose have been reported with HMG-CoA reductase inhibitors; however, the benefits of statin therapy (eg, reduction in the risk of myocardial infarction or stroke) far outweigh the risk of dysglycemia. If a patient develops diabetes mellitus during therapy, continue use of fluvastatin and encourage patient to adhere to healthy lifestyle regimens (eg, heart healthy dietary pattern, engage in physical activity, achieve and maintain a healthy body weight) (AHA/ACC [Grundy 2019]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatotoxicity: Increased AST or ALT has been reported; in most cases, elevations were transient and resolved or improved on continued therapy or after a brief interruption in therapy. Postmarketing reports of fatal and nonfatal hepatic failure have been reported and are rare. If serious hepatotoxicity with clinical symptoms and/or hyperbilirubinemia or jaundice occurs during treatment, interrupt therapy promptly. If an alternate etiology is not identified, do not restart fluvastatin. Possible drug-related hepatitis (rare) was observed that resolved upon discontinuation of treatment. Liver enzyme tests should be obtained at baseline and as clinically indicated and if signs/symptoms of liver injury occur. Ethanol may enhance the potential of adverse hepatic effects; instruct patients to avoid excessive ethanol consumption. Use has been found to be safe in those with active hepatitis C (Kondo 2012; Kurincic 2014).</p>
<p style="text-indent:-2em;margin-left:4em;">• Myopathy/Rhabdomyolysis: Rhabdomyolysis with acute renal failure secondary to myoglobinuria and/or myopathy has been reported; patients should be monitored closely. This risk is dose related and is increased with concurrent use of cyclosporine, erythromycin, fluconazole, or other lipid-lowering medications (eg, fibrates, niacin at doses ≥1 g/day). Use caution in patients with uncontrolled hypothyroidism, and those taking other drugs associated with myopathy (eg, colchicine); these patients are predisposed to myopathy. Immune-mediated necrotizing myopathy associated with HMG-CoA reductase inhibitors use has also been reported. Patients should be instructed to report unexplained muscle pain, tenderness, weakness, or brown urine, particularly if accompanied by malaise or fever. Prior to initiating a different HMG-CoA reductase inhibitor consider risk of immune-mediated necrotizing myopathy; monitor closely.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment and/or ethanol use: Use with caution in patients who consume large amounts of ethanol or have a history of liver disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Myasthenia gravis: May rarely worsen or precipitate myasthenia gravis (MG); monitor for worsening MG if treatment is initiated (AAN [Narayanaswami 2021]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; these patients are predisposed to myopathy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Use with caution in patients with advanced age; these patients are predisposed to myopathy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Surgical patients: Based on current research and clinical guidelines, HMG-CoA reductase inhibitors should be continued in the perioperative period for noncardiac and cardiac surgery (ACC/AHA [Hillis 2011]; ACC/AHA [Fleisher 2014]). Perioperative discontinuation of statin therapy is associated with an increased risk of cardiac morbidity and mortality.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Drug therapy should be only one component of multiple risk factor intervention in patients at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. In patients with congenital heart defect (CHD) or multiple risk factors for CHD, initiate therapy simultaneously with diet.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hyperlipidemia: Secondary causes of hyperlipidemia should be ruled out prior to therapy.</p></div>
<div class="block foc drugH1Div" id="F173480"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 20 mg, 40 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release 24 Hour, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lescol XL: 80 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 80 mg</p></div>
<div class="block geq drugH1Div" id="F173465"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F173489"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Fluvastatin Sodium Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $5.00 - $5.01</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg (per each): $5.00 - $5.01</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, 24-hour</b> (Fluvastatin Sodium ER Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">80 mg (per each): $8.76 - $9.24</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, 24-hour</b> (Lescol XL Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">80 mg (per each): $14.91</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866957"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 20 mg, 40 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release 24 Hour, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lescol XL: 80 mg [DSC]</p></div>
<div class="block admp drugH1Div" id="F52612877"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Fluvastatin may be taken without regard to meals.</p>
<p style="text-indent:0em;margin-left:2em;">Immediate-release capsules: Do not open capsules; do not use two 40 mg capsules for an 80 mg once daily dose; extended release formulation should be used.</p>
<p style="text-indent:0em;margin-left:2em;">Extended-release tablet: Do not break, chew, or crush; swallow whole.</p></div>
<div class="block adm drugH1Div" id="F173484"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Administer without regard to meals. Do not break, chew, or crush ER tablets; do not open IR capsules. Do not administer two 40 mg IR capsules at once.</p>
<p style="text-indent:-2em;margin-left:4em;">Bariatric surgery: Tablet, extended release: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate. Switch to IR capsule.</p></div>
<div class="block sts drugH1Div" id="F173500"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Protect from light.</p></div>
<div class="block usep drugH1Div" id="F53566978"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Adjunct to dietary therapy to reduce elevated total-C, LDL-C, and apo-B levels in patients with heterozygous familial hypercholesterolemia (HFH) and if LDC-C remains ≥190 mg/dL or if ≥160 mg/dL with family history of premature cardiovascular disease or presence of ≥2 cardiovascular risk factors [FDA approved in ages 10-16 years (girls ≥1 year postmenarche)]. Adjunct to dietary therapy to reduce elevated total cholesterol (total-C), LDL-C, triglyceride, and apolipoprotein B (apo-B) levels and to increase HDL-C in primary hypercholesterolemia, and mixed dyslipidemia (Fredrickson types IIa and IIb) (FDA approved in adults); to slow the progression of coronary atherosclerosis in patients with coronary heart disease (FDA approved in adults); to reduce risk of coronary revascularization procedures in patients with coronary heart disease (FDA approved in adults) </p></div>
<div class="block mst drugH1Div" id="F173556"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Fluvastatin may be confused with fluoxetine, nystatin, pitavastatin</p>
<p style="text-indent:2em;">HMG-CoA reductase inhibitors (when referred to as "statins") may be confused with nystatin.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F173542"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2C8 (minor), CYP2C9 (major), CYP2D6 (minor), CYP3A4 (minor), OATP1B1/1B3 (SLCO1B1/1B3); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F173474"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Abiraterone Acetate: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors (Statins).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Acipimox: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors (Statins).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpelisib: May decrease the serum concentration of CYP2C9 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Asunaprevir: May increase the serum concentration of HMG-CoA Reductase Inhibitors (Statins).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atazanavir: May increase the serum concentration of Fluvastatin. Management: When used with atazanavir/cobicistat, initiate fluvastatin at the lowest recommended dose and monitor clinical response (particularly any evidence of toxicity) to dose titration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bezafibrate: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors (Statins). Bezafibrate may increase the serum concentration of HMG-CoA Reductase Inhibitors (Statins). More specifically, bezafibrate may increase the serum concentration of fluvastatin Management: Avoid use of bezafibrate and HMG-CoA reductase inhibitors (statins) unless strictly indicated due to the increased of muscle toxicity (including rhabdomyolysis). In patients who may be predisposed to myopathy, concomitant use is contraindicated.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholestyramine Resin: May decrease the serum concentration of Fluvastatin. Management: Separate the administration of fluvastatin and cholestyramine to maximize fluvastatin absorption. Administer fluvastatin 2 to 4 hours, or longer, after cholestyramine administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ciprofibrate: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors (Statins). Management: Avoid the use of HMG-CoA reductase inhibitors and ciprofibrate if possible. If concomitant therapy is considered, benefits should be carefully weighed against the risks, and patients should be monitored closely for signs/symptoms of muscle toxicity.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cobicistat: May increase the serum concentration of Fluvastatin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Colchicine: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors (Statins). Colchicine may increase the serum concentration of HMG-CoA Reductase Inhibitors (Statins). HMG-CoA Reductase Inhibitors (Statins) may increase the serum concentration of Colchicine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): May increase the serum concentration of Fluvastatin. Management: Limit fluvastatin to 20 mg twice daily and avoid use of fluvastatin extended-release tablets in patients who are also receiving cyclosporine and monitor for fluvastatin toxicities (eg, myalgia, myopathy, rhabdomyolysis).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C9 Inducers (Moderate): May decrease the serum concentration of Fluvastatin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C9 Inhibitors (Moderate): May increase the serum concentration of Fluvastatin. Management: Fluvastatin should be used at the lowest effective dose and should not exceed 20 mg twice daily when combined with moderate CYP2C9 inhibitors. Avoid coadministration of fluvastatin extended-release tablets with moderate CYP2C9 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daclatasvir: May increase the serum concentration of HMG-CoA Reductase Inhibitors (Statins).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DAPTOmycin: HMG-CoA Reductase Inhibitors (Statins) may enhance the adverse/toxic effect of DAPTOmycin. Specifically, the risk of skeletal muscle toxicity may be increased.  Management: Consider temporarily stopping statin (HMG-CoA reductase inhibitor) therapy prior to daptomycin. If daptomycin is used with a statin, creatine phosphokinase (CPK) monitoring could be considered.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Darolutamide: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elbasvir and Grazoprevir: May increase the serum concentration of Fluvastatin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eltrombopag: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Encorafenib: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etravirine: May increase the serum concentration of Fluvastatin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fenofibrate and Derivatives: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors (Statins).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosphenytoin-Phenytoin: Fluvastatin may increase the serum concentration of Fosphenytoin-Phenytoin. Fosphenytoin-Phenytoin may increase the serum concentration of Fluvastatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fostemsavir: May increase the serum concentration of HMG-CoA Reductase Inhibitors (Statins). Management: Use the lowest possible starting statin dose and monitor patients closely for statin-related adverse effects (eg, muscle aches and pains) during coadministration with fostemsavir.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors (Statins). Specifically, the risk for muscle toxicities, including rhabdomyolysis may be significantly increased. Management: Avoid concurrent use whenever possible. Use is listed as contraindicated in product characteristic summaries in several countries, although UK labeling suggests that use could be considered under exceptional circumstances and with close supervision.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gemfibrozil: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors (Statins).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glecaprevir and Pibrentasvir: May increase the serum concentration of HMG-CoA Reductase Inhibitors (Statins). Management: Use the lowest statin dose possible if combined with glecaprevir/pibrentasvir and monitor for increased statin effects/toxicities. Avoid concomitant use with atorva-, simva-, or lovastatin. Limit rosuvastatin to 10 mg daily and reduce pravastatin dose 50%<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">GlyBURIDE: May increase the serum concentration of Fluvastatin. Fluvastatin may increase the serum concentration of GlyBURIDE.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lanthanum: May decrease the serum concentration of HMG-CoA Reductase Inhibitors (Statins). Management: Administer HMG-CoA reductase inhibitors (eg, statins) at least two hours before or after lanthanum.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leniolisib: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Letermovir: May increase the serum concentration of HMG-CoA Reductase Inhibitors (Statins).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumacaftor and Ivacaftor: May decrease the serum concentration of CYP2C9 Substrates (High Risk with Inhibitors or Inducers). Lumacaftor and Ivacaftor may increase the serum concentration of CYP2C9 Substrates (High Risk with Inhibitors or Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Niacin: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors (Statins).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir: May increase the serum concentration of Fluvastatin. Management: Canadian product labeling recommends use of the lowest fluvastatin dose with this combination.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pretomanid: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Raltegravir: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors (Statins).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Red Yeast Rice: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors (Statins).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Repaglinide: HMG-CoA Reductase Inhibitors (Statins) may increase the serum concentration of Repaglinide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">RifAMPin: May decrease the serum concentration of Fluvastatin. Specifically, this occurs with prolonged coadministration. RifAMPin may increase the serum concentration of Fluvastatin. Specifically, this occurs upon rifampin initiation.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rifapentine: May decrease the serum concentration of CYP2C9 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Roxadustat: May increase the serum concentration of HMG-CoA Reductase Inhibitors (Statins).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rupatadine: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors (Statins). Specifically, the risk for increased CPK and/or other muscle toxicities may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Teriflunomide: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trabectedin: HMG-CoA Reductase Inhibitors (Statins) may enhance the myopathic (rhabdomyolysis) effect of Trabectedin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trofinetide: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors). Management: Avoid concurrent use with OATP1B1/1B3 substrates for which small changes in exposure may be associated with serious toxicities. Monitor for evidence of an altered response to any OATP1B1/1B3 substrate if used together with trofinetide.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): HMG-CoA Reductase Inhibitors (Statins) may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voclosporin: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voxilaprevir: May increase the serum concentration of HMG-CoA Reductase Inhibitors (Statins). Management: Use the lowest statin dose possible if combined with voxilaprevir and monitor patients for increased statin effects/toxicities. Avoid concomitant use of voxilaprevir with rosuvastatin or pitavastatin, and limit pravastatin doses to 40 mg daily.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block foi drugH1Div" id="F173501"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Food reduces rate but not the extent of absorption. Management: Administer without regard to meals.</p></div>
<div class="block dic drugH1Div" id="F173492"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Generally, patients should be placed on a standard cholesterol-lowering diet and other lifestyle modifications for 3 to 6 months prior to the initiation of drug therapy. The diet should be continued during drug therapy. However, for patients with advanced risk factors (eg, known coronary heart disease), drug therapy may be initiated concurrently with diet modification. </p>
<p style="text-indent:0em;margin-top:2em;">Red yeast rice contains variable amounts of several compounds that are structurally similar to HMG-CoA reductase inhibitors, primarily monacolin K (or mevinolin) which is structurally identical to lovastatin; concurrent use of red yeast rice with HMG-CoA reductase inhibitors may increase the incidence of adverse and toxic effects (Lapi 2008; Smith 2003). </p></div>
<div class="block rep_considerations drugH1Div" id="F49306608"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Adequate contraception is recommended if an HMG-CoA reductase inhibitor (statin) is required in patients who may become pregnant (AHA/ACC [Grundy 2019]; CCS [Pearson 2021]). Use of fluvastatin is contraindicated in patients who could become pregnant. Patients planning to become pregnant should discuss their lifetime risk of cardiovascular disease, as well as risks and benefits of statin therapy with their health care team (CCS [Pearson 2021]). When appropriate, statins can be discontinued 1 to 2 months prior to conception (AHA/ACC [Grundy 2019]).</p>
<p style="text-indent:0em;margin-top:2em;">When a statin is needed in a patient of reproductive potential, a more hydrophilic option (eg, pravastatin, rosuvastatin) may be preferred to limit placental transfer (CCS [Pearson 2021]).</p></div>
<div class="block pri drugH1Div" id="F173490"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">In healthy pregnancies, changes in lipid synthesis occur that are required for normal placental and fetal growth. Low-density lipoprotein cholesterol and triglycerides increase as pregnancy progresses and decline postpartum. HMG-CoA reductase inhibitors (statins) decrease the synthesis of cholesterol and substances derived from cholesterol. Therefore, based on the mechanism of action, in utero exposure may cause fetal harm (Lecarpentier 2012); however, data from available studies have not shown an increased risk of major congenital anomalies following first-trimester exposure (Bateman 2015; Chang 2021; Vahedian-Azimi 2021a). Additional data are needed to evaluate other pregnancy outcomes, such as miscarriage (Vahedian-Azimi 2021b).</p>
<p style="text-indent:0em;margin-top:2em;">Because there is potential for fetal harm, statins should be discontinued once pregnancy is recognized (AHA/ACC [Grundy 2019]; Brunham 2018). If lipid-lowering therapy during pregnancy is required, it should be individualized based on the therapeutic needs of the patient, considering the lifetime risk of untreated disease, use of nonstatin therapies, as well as the known risks and benefits of statins. Based on limited data, when a statin is needed in a pregnant patient, a more hydrophilic option (eg, pravastatin, rosuvastatin) may be preferred. Lipophilic statins (eg, atorvastatin, fluvastatin, lovastatin, simvastatin, pitavastatin) may be more likely to cross the placenta and increase the risk of congenital malformations (AHA/ACC [Grundy 2019]; CCS [Pearson 2021]; Lecarpentier 2012).</p>
<p style="text-indent:0em;margin-top:2em;">Additional data are needed to clarify the role of statins for the prevention of atherosclerotic cardiovascular disease in at-risk pregnant patients (AHA/ACC [Grundy 2019]; CCS [Pearson 2021]; Parikh 2021).</p></div>
<div class="block mopp drugH1Div" id="F53566977"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Manufacturer's labeling: Consider neuromuscular and serologic testing if immune-mediated necrotizing myopathy is suspected.​</p>
<p style="text-indent:-2em;margin-left:2em;">Pediatric patients: Baseline: ALT, AST, and creatine phosphokinase levels (CPK); fasting lipid panel (FLP) and repeat ALT and AST should be checked after 4 weeks of therapy; if no myopathy symptoms or laboratory abnormalities, then monitor FLP, ALT, and AST every 3 to 4 months during the first year and then every 6 months thereafter (NHLBI 2011).</p>
<p style="text-indent:-2em;margin-left:2em;">Adults:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>2013 ACC/AHA Blood Cholesterol Guideline recommendations (Stone 2013):</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Lipid panel (total cholesterol, HDL, LDL, triglycerides):</b> Baseline lipid panel; fasting lipid profile within 4 to 12 weeks after initiation or dose adjustment and every 3 to 12 months (as clinically indicated) thereafter. If 2 consecutive LDL levels are &lt;40 mg/dL, consider decreasing the dose.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Hepatic transaminase levels:</b> Baseline measurement of hepatic transaminase levels (ie, ALT); measure hepatic function if symptoms suggest hepatotoxicity (eg, unusual fatigue or weakness, loss of appetite, abdominal pain, dark-colored urine or yellowing of skin or sclera) during therapy.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>CPK:</b> CPK should not be routinely measured. Baseline CPK measurement is reasonable for some individuals (eg, family history of statin intolerance or muscle disease, clinical presentation, concomitant drug therapy that may increase risk of myopathy). May measure CPK in any patient with symptoms suggestive of myopathy (pain, tenderness, stiffness, cramping, weakness, or generalized fatigue).</p>
<p style="text-indent:-2em;margin-left:6em;">Evaluate for new-onset diabetes mellitus during therapy; if diabetes develops, continue statin therapy and encourage adherence to a heart-healthy diet, physical activity, a healthy body weight, and tobacco cessation.</p>
<p style="text-indent:-2em;margin-left:4em;">If patient develops a confusional state or memory impairment, may evaluate patient for nonstatin causes (eg, exposure to other drugs), systemic and neuropsychiatric causes, and the possibility of adverse effects associated with statin therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Manufacturer recommendations:</i> Liver enzyme tests at baseline and repeated when clinically indicated. Measure CPK when myopathy is being considered. Upon initiation or titration, lipid panel should be analyzed at 4 weeks.</p></div>
<div class="block pha drugH1Div" id="F173468"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Acts by competitively inhibiting 3-hydroxyl-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the reduction of HMG-CoA to mevalonate; this is an early rate-limiting step in cholesterol biosynthesis. HDL is increased while total, LDL, and VLDL cholesterols; apolipoprotein B; and plasma triglycerides are decreased. In addition to the ability of HMG-CoA reductase inhibitors to decrease levels of high-sensitivity C-reactive protein (hsCRP), they also possess pleiotropic properties including improved endothelial function, reduced inflammation at the site of the coronary plaque, inhibition of platelet aggregation, and anticoagulant effects (de Denus 2002; Ray 2005).</p></div>
<div class="block phk drugH1Div" id="F173486"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Onset of action: Peak effect: Maximal LDL-C reductions achieved within 4 weeks</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: V<sub>dss</sub>: 0.35 L/kg </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: 98% </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Hepatic to inactive and active metabolites (oxidative metabolism via CYP2C9 [~75%], CYP2C8 [~5%], and CYP3A4 [~20%] isoenzymes); active forms do not circulate systemically; extensive (saturable) first-pass hepatic extraction </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Bioavailability: Absolute: Immediate-release: 24%; Extended-release: ~29% (increased by ~50% when administered with a high-fat meal)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: Immediate-release: ~3 hours; Extended-release: 7.3 to 10.5 hours (due to prolonged absorption time) (Barilla 2004) </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Immediate-release: &lt;1 hour (delayed more than 2-fold when administered with food as compared to administering 4 hours after the evening meal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Extended-release: ~3 hours (minimally affected by low-fat meals; however, with a high-fat meal, delayed by 2-fold)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Feces (~90%; &lt;2% unchanged); urine (~5%) </p></div>
<div class="block phksp drugH1Div" id="F51192640"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: In moderate to severe renal impairment (CrCl 10 to 40 mL/minute), AUC and C<sub>max</sub> increased ~1.2-fold after administration of a single dose of 40 mg immediate-release fluvastatin; in ESRD on hemodialysis, the AUC increased ~1.5-fold.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: AUC and C<sub>max</sub> increase ~2.5-fold after administration of a single dose of 40 mg immediate-release fluvastatin.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F173493"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Lescol</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Lescol</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Fluvastatin | Fluvastatin accord | Fluvastatin actavis | Fluvastatin hexal | Fluvastatin sandoz | Fluvastatin Stada | Lescol | Lescol mr</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Lescol | Vastin</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Fluvas | Lescol</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Fluvastatin sandoz | Fluvastatine EG | Fluvastatine Mylan | Fluvastatine Teva | Lescol | Lescol-exel</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Lescol | Lescol xl | Luvinsta</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Fluvastat | Lescol</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Fluvastatin Mepha | Fluvastatin sandoz | Fluvastatin Teva | Lescol</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Leucol</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Lai kuo ke | Lai shi ke | Lescol</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Lescol | Sanacard</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Fluvastatin actavis | Fluvastatin mylan | Fluvastatin Teva | Lescol</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Cranoc | Fluvastatin 1A Pharma | Fluvastatin abz | Fluvastatin actavis | Fluvastatin AL | Fluvastatin beta | Fluvastatin ct | Fluvastatin hexal | Fluvastatin holsten | Fluvastatin puren | Fluvastatin ratiopharm | Fluvastatin sandoz | Fluvastatin Stada | Fluvastatin Teva | Fluvastatin Winthrop | Lescol | Locol</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Lescol</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Lescol</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Fluvastatin | Fluvastatin accord | Lescol | Lescol xl</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Fluvastatin | Lescol</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Digaril | Fluvastatina Actavis | Fluvastatina alter | Fluvastatina apotex | Fluvastatina aristo | Fluvastatina Aristogen | Fluvastatina Bexal | Fluvastatina Cinfa | Fluvastatina Edigen | Fluvastatina kern pharma | Fluvastatina Mylan | Fluvastatina Normon | Fluvastatina Ratio | Fluvastatina Sandoz | Fluvastatina Teva | Lescol | Liposit | Lymetel | Vaditon | Vaditon Prolib | Vaditon prolib</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Canef | Fluvastatin actavis | Fluvastatin mylan | Fluvastatin sandoz | Lescol</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Fluvastatine accord | Fluvastatine Actavis | Fluvastatine Arrow | Fluvastatine Biogaran | Fluvastatine Cristers | Fluvastatine EG | Fluvastatine evolugen | Fluvastatine isomed | Fluvastatine Mylan | Fluvastatine Qualimed | Fluvastatine Qualimed LP | Fluvastatine ranbaxy | Fluvastatine ratio | Fluvastatine sandoz | Fluvastatine Teva LP | Fluvastatine winthrop | Fluvastatine Zydus | Fractal | Lescol</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Cadaff xl | Fluvastatin | Fluvastatin sandoz | Lescol | Luvinsta | Nandovar | Stefluvin</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Hovalin | Lescol | Lescol xl</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Lescol</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Flovella | Fluvascol</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Fluvastatin sandoz | Lescol | Lochol | Stipatin</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Lescol</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Lescol | Lochol | Luvinsta | Statease</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Lescol</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Fluvastatina | Fluvastatina Act | Fluvastatina DocG | Fluvastatina EG | Fluvastatina MG | Fluvastatina San | Fluvastatina Sandoz | Fluvastatina winthrop | Lescol | Lipaxan | Primesin</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Lescol</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Fluvastatin | Lochol</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Lescol</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Lescol | Lescol xl | Xilep | Xilep xl | Zaireb XL</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Lescol</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Lescol</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Fluvastatin actavis | Lescol | Lescol xl</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Lescol | Locol</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Lescol | Lescol xl</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Lescol</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Lescol | Vastaflux</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Lescol | Lescol xl</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Lescol</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Canef | Fluvastatin | Fluvastatin sandoz | Fluvastatine | Fluvastatine accord | Fluvastatine Actavis | Fluvastatine CF | Fluvastatine Mylan | Fluvastatine ratiopharm | Lescol | Vaditon</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Fluvastatin | Fluvastatin abz | Fluvastatin accord | Fluvastatin holsten | Fluvastatin ratiopharm | Lescol</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Lescol</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Fluvastatin | Lescol</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Lescol | Luvastin | Luvista</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Lescol</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Fluvastatin | Lescol</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Canef | Cardiol | Fluvastatin | Fluvastatina Actavis | Fluvastatina alter | Fluvastatina Ciclum | Fluvastatina generis | Fluvastatina Germed | Fluvastatina Labesfal | Fluvastatina Mepha | Fluvastatina Mylan | Fluvastatina Ratiopharm | Fluvastatina Sandoz | Fluvastatina Teva | Lescol</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Lescol</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Lescol XL</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Lescol</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Lescol | Lescol forte</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Lescol</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Fluvastatin bluefish | Lescol</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Lescol</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Fluvastatin actavis | Lescol</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Fluvastatin mylan | Lescol</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Lescol</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Fluvasta | Lescol</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Lescol</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Fluvastatin xl | Lescol</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Lescol | Lescol xl</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Lescol</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Lescol | Vaticol xl</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Lescol xl</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-34383728">
<a name="34383728"></a>Alanazi NS, Alenazi TS, Alenzi KA. Hepatotoxicity induced by fluvastatin: a reversible acute cholestatic liver injury. <i>Am J Case Rep</i>. 2021;22:e931418. doi:10.12659/AJCR.931418<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvastatin-pediatric-drug-information/abstract-text/34383728/pubmed" id="34383728" target="_blank">34383728</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22148003">
<a name="22148003"></a>Baek SD, Jang SJ, Park SE, et al. Fatal rhabdomyolysis in a patient with liver cirrhosis after switching from simvastatin to fluvastatin. <i>J Korean Med Sci</i>. 2011;26(12):1634-1637. doi:10.3346/jkms.2011.26.12.1634<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvastatin-pediatric-drug-information/abstract-text/22148003/pubmed" id="22148003" target="_blank">22148003</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14872552">
<a name="14872552"></a>Barilla D, Prasad P, Hubert M, Gumbhir-Shah K. Steady-state pharmacokinetics of fluvastatin in healthy subjects following a new extended release fluvastatin tablet, Lescol XL. <i>Biopharm Drug Dispos</i>. 2004;25(2):51-59.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvastatin-pediatric-drug-information/abstract-text/14872552/pubmed" id="14872552" target="_blank">14872552</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25784688">
<a name="25784688"></a>Bateman BT, Hernandez-Diaz S, Fischer MA, et al. Statins and congenital malformations: cohort study. <i>BMJ</i>. 2015;350:h1035. doi:10.1136/bmj.h1035<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvastatin-pediatric-drug-information/abstract-text/25784688/pubmed" id="25784688" target="_blank">25784688</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22962670">
<a name="22962670"></a>Berglund L, Brunzell JD, Goldberg AC, et al, “Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline,” <i>J Clin Endocrinol Metab</i>, 2012, 97(9):2969-89.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvastatin-pediatric-drug-information/abstract-text/22962670/pubmed" id="22962670" target="_blank">22962670</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27838723">
<a name="27838723"></a>Bibbins-Domingo K, Grossman DC, Curry, SJ, et al; US Preventive Services Task Force. Statin use for the primary prevention of cardiovascular disease in adults: US Preventive Services Task Force recommendation statement. <i>JAMA</i>. 2016;316(19):1997-2007. doi: 10.1001/jama.2016.15450.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvastatin-pediatric-drug-information/abstract-text/27838723/pubmed" id="27838723" target="_blank">27838723</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30527143">
<a name="30527143"></a>Brunham LR, Ruel I, Aljenedil S, et al. Canadian Cardiovascular Society position statement on familial hypercholesterolemia: update 2018. <i>Can J Cardiol</i>. 2018;34(12):1553-1563. doi:10.1016/j.cjca.2018.09.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvastatin-pediatric-drug-information/abstract-text/30527143/pubmed" id="30527143" target="_blank">30527143</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, "Canadian Diabetes Association 2013 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada," <i>Can J Diabetes</i>, 2013, 35(Suppl 1):1-212.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22870499">
<a name="22870499"></a>Castro C and Gourley M, "Diagnosis and Treatment of Inflammatory Myopathy: Issues and Management," <i>Ther Adv Musculoskelet Dis</i>, 2012, 4(2):111-20.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvastatin-pediatric-drug-information/abstract-text/22870499/pubmed" id="22870499" target="_blank">22870499</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34967881">
<a name="34967881"></a>Chang JC, Chen YJ, Chen IC, Lin WS, Chen YM, Lin CH. Perinatal outcomes after statin exposure during pregnancy. <i>JAMA Netw Open</i>. 2021;4(12):e2141321. doi:10.1001/jamanetworkopen.2021.41321<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvastatin-pediatric-drug-information/abstract-text/34967881/pubmed" id="34967881" target="_blank">34967881</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18596007">
<a name="18596007"></a>Daniels SR, Greer FR, and Committee on Nutrition, "Lipid Screening and Cardiovascular Health in Childhood," <i>Pediatrics</i>, 2008, 122(1):198-208.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvastatin-pediatric-drug-information/abstract-text/18596007/pubmed" id="18596007" target="_blank">18596007</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12398573">
<a name="12398573"></a>de Denus S and Spinler SA, “Early Statin Therapy for Acute Coronary Syndromes,” <i>Ann Pharmacother</i>, 2002, 36(11):1749-58.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvastatin-pediatric-drug-information/abstract-text/12398573/pubmed" id="12398573" target="_blank">12398573</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11368702">
<a name="11368702"></a>“Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III),” <i>JAMA</i>, 2001, 285(19):2486-97.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvastatin-pediatric-drug-information/abstract-text/11368702/pubmed" id="11368702" target="_blank">11368702</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18689579">
<a name="18689579"></a>Fernandez AB, Karas RH, Alsheikh-Ali AA, et al, “Statins and Interstitial Lung Disease: A Systematic Review of the Literature and of Food and Drug Administration Adverse Event Reports,” <i>Chest</i>, 2008, 134(4):824-30.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvastatin-pediatric-drug-information/abstract-text/18689579/pubmed" id="18689579" target="_blank">18689579</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23166211">
<a name="23166211"></a>Fihn SD, Gardin JM, Abrams J, et al, “2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons,” <i>Circulation</i>, 2012, 126(25):3097-137.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvastatin-pediatric-drug-information/abstract-text/23166211/pubmed" id="23166211" target="_blank">23166211</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25085961">
<a name="25085961"></a>Fleisher LA, Fleischmann KE, Auerbach AD, et al. 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2014;130(24):e278-e333.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvastatin-pediatric-drug-information/abstract-text/25085961/pubmed" id="25085961" target="_blank">25085961</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Fluvastatin capsules [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals Inc; August 2020.</div>
</li>
<li>
<div class="reference">
                  Fluvastatin capsules [product monograph]. Toronto, Ontario, Canada: Teva Canada Limited; November 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11136683">
<a name="11136683"></a>Fonarow GC, French WJ, Parsons LS, et al, “Use of Lipid-Lowering Medications at Discharge in Patients With Acute Myocardial Infarction: Data From the National Registry of Myocardial Infarction 3,” <i>Circulation</i>, 2001, 103(1):38-44.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvastatin-pediatric-drug-information/abstract-text/11136683/pubmed" id="11136683" target="_blank">11136683</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23032657">
<a name="23032657"></a>Godfrey LM, Erramouspe J, and Cleveland KW, "Teratogenic Risk of Statins in Pregnancy," <i>Ann Pharmacother</i>, 2012, 46(10):1419-24.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvastatin-pediatric-drug-information/abstract-text/23032657/pubmed" id="23032657" target="_blank">23032657</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30586774">
<a name="30586774"></a>Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Circulation</i>. 2019;139(25):e1082-e1143. doi:10.1161/CIR.0000000000000625<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvastatin-pediatric-drug-information/abstract-text/30586774/pubmed" id="30586774" target="_blank">30586774</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11914253">
<a name="11914253"></a>Heeschen C, Hamm CW, Laufs U, et al, “Withdrawal of Statins Increases Event Rates in Patients With Acute Coronary Syndromes,” <i>Circulation</i>, 2002, 105(12):1446-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvastatin-pediatric-drug-information/abstract-text/11914253/pubmed" id="11914253" target="_blank">11914253</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22064600">
<a name="22064600"></a>Hillis LD, Smith PK, Anderson JL, et al. 2011 ACCF/AHA guideline for coronary artery bypass graft surgery: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines [published correction appears in <i>Circulation</i>. 2012;126(7):e105]. <i>Circulation</i>. 2011;124(23):2610-2642. doi: 10.1161/CIR.0b013e31823b5fee.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvastatin-pediatric-drug-information/abstract-text/22064600/pubmed" id="22064600" target="_blank">22064600</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28551957">
<a name="28551957"></a>Holmsen ST, Bakkebø T, Seferowicz M, Retterstøl K. Statins and breastfeeding in familial hypercholesterolaemia. <i>Tidsskr Nor Laegeforen</i>. 2017;137(10):686-687. doi:10.4045/tidsskr.16.0838<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvastatin-pediatric-drug-information/abstract-text/28551957/pubmed" id="28551957" target="_blank">28551957</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26184102">
<a name="26184102"></a>Huang CY, Chung SD, Kao LT, Lin HC, Wang LH. Statin use is associated with bladder pain syndrome/interstitial cystitis: a population-based case-control study. <i>Urol Int</i>. 2015;95(2):227-232.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvastatin-pediatric-drug-information/abstract-text/26184102/pubmed" id="26184102" target="_blank">26184102</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24682347">
<a name="24682347"></a>January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society [published online March 28, 2014]. <i>Circulation</i>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvastatin-pediatric-drug-information/abstract-text/24682347/pubmed" id="24682347" target="_blank">24682347</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25911072">
<a name="25911072"></a>Jacobson TA, Ito MK, Maki KC, et al. National lipid association recommendations for patient-centered management of dyslipidemia: part 1--full report. <i>J Clin Lipidol</i>. 2015;9(2):129-169. doi: 10.1016/j.jacl.2015.02.003.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvastatin-pediatric-drug-information/abstract-text/25911072/pubmed" id="25911072" target="_blank">25911072</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28437620">
<a name="28437620"></a>Jellinger PS, Handelsman Y, Rosenblit PD, et al. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. <i>Endocr Pract</i>. 2017;23(suppl 2):1-87. doi: 10.4158/EP171764.APPGL.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvastatin-pediatric-drug-information/abstract-text/28437620/pubmed" id="28437620" target="_blank">28437620</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22863265">
<a name="22863265"></a>Kondo C, Atsukawa M, Tsubota A, et al. An open-label randomized controlled study of pegylated interferon/ribavirin combination therapy for chronic hepatitis C with versus without fluvastatin. <i>J Viral Hepatitis</i>. 2012;19(9):615-622.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvastatin-pediatric-drug-information/abstract-text/22863265/pubmed" id="22863265" target="_blank">22863265</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25679302">
<a name="25679302"></a>Kulik A, Ruel M, Jneid H, et al. Secondary prevention after coronary artery bypass graft surgery: a scientific statement from the American Heart Association. <i>Circulation</i>. 2015;131(10):927-964. doi: 10.1161/CIR.0000000000000182.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvastatin-pediatric-drug-information/abstract-text/25679302/pubmed" id="25679302" target="_blank">25679302</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24080608">
<a name="24080608"></a>Kurincic ST, Lesnicar G, Poljak M, et al. Impact of Added Fluvastatin to Standard-of-Care Treatment on Sustained Virological Response in Naïve Chronic Hepatitis C Patients Infected with Genotypes 1 and 3. <i>Interviriology</i> 2014;57(1):23-30.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvastatin-pediatric-drug-information/abstract-text/24080608/pubmed" id="24080608" target="_blank">24080608</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18637891">
<a name="18637891"></a>Lapi F, Gallo E, Bernasconi S, et al. Myopathies associated with red yeast rice and liquorice: spontaneous reports from the Italian Surveillance System of Natural Health Products. <i>Br J Clin Pharmacol</i>. 2008;66(4):572-574.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvastatin-pediatric-drug-information/abstract-text/18637891/pubmed" id="18637891" target="_blank">18637891</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15755765">
<a name="15755765"></a>LaRosa JC, Grundy SM, Waters DD, et al, “Intensive Lipid Lowering With Atorvastatin in Patients With Stable Coronary Disease,” <i>N Engl J Med</i>, 2005, 352(14):1425-35.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvastatin-pediatric-drug-information/abstract-text/15755765/pubmed" id="15755765" target="_blank">15755765</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22480340">
<a name="22480340"></a>Lecarpentier E, Morel O, Fournier T, et al, "Statins and Pregnancy: Between Supposed Risks and Theoretical Benefits," <i>Drugs</i>, 2012, 72(6):773-88.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvastatin-pediatric-drug-information/abstract-text/22480340/pubmed" id="22480340" target="_blank">22480340</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17513620">
<a name="17513620"></a>LeManach Y, Godet G, Coriat P, et al, “The Impact of Postoperative Discontinuation or Continuation of Chronic Statin Therapy on Cardiac Outcome After Major Vascular Surgery,” <i>Anesth Analg</i>, 2007, 104(6):1326-33.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvastatin-pediatric-drug-information/abstract-text/17513620/pubmed" id="17513620" target="_blank">17513620</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lescol.2020.09">
<a name="Lescol.2020.09"></a>Lescol XL (fluvastatin) [prescribing information]. Princeton, NJ: Sandoz Inc; November 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36031461">
<a name="36031461"></a>Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Solution Set Oversight Committee. <i>J Am Coll Cardiol</i>. 2022;80(14):1366-1418. doi:10.1016/j.jacc.2022.07.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvastatin-pediatric-drug-information/abstract-text/36031461/pubmed" id="36031461" target="_blank">36031461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17377073">
<a name="17377073"></a>McCrindle BW, Urbina EM, Dennison BA, et al, "Drug Therapy of High-Risk Lipid Abnormalities in Children and Adolescents: A Scientific Statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, With the Council on Cardiovascular Nursing," <i>Circulation</i>, 2007, 115(14):1948-67.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvastatin-pediatric-drug-information/abstract-text/17377073/pubmed" id="17377073" target="_blank">17377073</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16971976">
<a name="16971976"></a>McPherson R, Frohlich J, Fodor G, et al, “Canadian Cardiovascular Society Position Statement--Recommendations for the Diagnosis and Treatment of Dyslipidemia and Prevention of Cardiovascular Disease,” [published correction appears in <i>Can J Cardiol</i>. 2006, 22(12):1077]. <i>Can J Cardiol</i>. 2006;22(11):913-927.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvastatin-pediatric-drug-information/abstract-text/16971976/pubmed" id="16971976" target="_blank">16971976</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12114036">
<a name="12114036"></a>“MRC/BHF Heart Protection Study of Cholesterol Lowering With Simvastatin in 20,536 High-Risk Individuals: A Randomised Placebo-Controlled Trial. Heart Protection Study Collaborative Group,” <i>Lancet</i>, 2002, 360(9326):7-22.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvastatin-pediatric-drug-information/abstract-text/12114036/pubmed" id="12114036" target="_blank">12114036</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33144515">
<a name="33144515"></a>Narayanaswami P, Sanders DB, Wolfe G, et al. International consensus guidance for management of myasthenia gravis: 2020 update. <i>Neurology</i>. 2021;96(3):114-122. doi:10.1212/WNL.0000000000011124<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvastatin-pediatric-drug-information/abstract-text/33144515/pubmed" id="33144515" target="_blank">33144515</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  National Heart, Lung, and Blood Institute, "Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents," Clinical Practice Guidelines, 2011, National Institutes of Health. Available at <a href="http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf%20" target="_blank">http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf </a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33779213">
<a name="33779213"></a>Parikh NI, Gonzalez JM, Anderson CAM, et al; American Heart Association Council on Epidemiology and Prevention; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular and Stroke Nursing; and the Stroke Council. Adverse pregnancy outcomes and cardiovascular disease risk: unique opportunities for cardiovascular disease prevention in women: a scientific statement from the American Heart Association. <i>Circulation</i>. 2021;143(18):e902-e916. doi:10.1161/CIR.0000000000000961<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvastatin-pediatric-drug-information/abstract-text/33779213/pubmed" id="33779213" target="_blank">33779213</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12215610">
<a name="12215610"></a>Pasternak RC, Smith SC Jr, Bairey-Merz CN, et al, “ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins,” <i>Stroke</i>, 2002, 33(9):2337-41. Available at http://stroke.ahajournals.org/cgi/content/short/33/9/2337
                     <span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvastatin-pediatric-drug-information/abstract-text/12215610/pubmed" id="12215610" target="_blank">12215610</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33781847">
<a name="33781847"></a>Pearson GJ, Thanassoulis G, Anderson TJ, et al. 2021 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults. <i>Can J Cardiol.</i> 2021;26:S0828-282X(21)00165-3. doi:10.1016/j.cjca.2021.03.016<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvastatin-pediatric-drug-information/abstract-text/33781847/pubmed" id="33781847" target="_blank">33781847</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12551878">
<a name="12551878"></a>Pearson TA, Mensah GA, Alexander RW, et al, “Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: A Statement for Healthcare Professionals From the Centers for Disease Control and Prevention and the American Heart Association,” <i>Circulation</i>, 2003, 107(3):499-511.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvastatin-pediatric-drug-information/abstract-text/12551878/pubmed" id="12551878" target="_blank">12551878</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8615304">
<a name="8615304"></a>Phillips BG, Yim JM, Brown EJ Jr, et al, “Pharmacologic Profile of Survivors of Acute Myocardial Infarction at United States Academic Hospitals,” <i>Am Heart J</i>, 1996, 131(5):872-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvastatin-pediatric-drug-information/abstract-text/8615304/pubmed" id="8615304" target="_blank">8615304</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Pignone M. Low-density lipoprotein cholesterol-lowering therapy in the primary prevention of cardiovascular disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 20, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12695283">
<a name="12695283"></a>Poldermans D, Bax JJ, Kertai MD, et al, “Statins Are Associated With a Reduced Incidence of Perioperative Mortality in Patients Undergoing Major Noncardiac Vascular Surgery,” <i>Circulation</i>, 2003, 107(14):1848-51.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvastatin-pediatric-drug-information/abstract-text/12695283/pubmed" id="12695283" target="_blank">12695283</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16226165">
<a name="16226165"></a>Ray KK and Cannon CP. The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes. <i>J Am Coll Cardiol</i>. 2005;46(8):1425-1433.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvastatin-pediatric-drug-information/abstract-text/16226165/pubmed" id="16226165" target="_blank">16226165</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18997196">
<a name="18997196"></a>Ridker PM, Danielson E, Fonseca FAH, et al, “Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein,” <i>N Engl J Med</i>, 2008, 359(21):2195-207.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvastatin-pediatric-drug-information/abstract-text/18997196/pubmed" id="18997196" target="_blank">18997196</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Rosenson.2019">
<a name="Rosenson.2019"></a>Rosenson RS, Hayward RA, Lopez-Sendon J. Management of low density lipoprotein cholesterol (LDL-C) in the secondary prevention of cardiovascular disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 3, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12686036">
<a name="12686036"></a>Sever PS, Dahlof B, Poulter NR, et al, “Prevention of Coronary and Stroke Events With Atorvastatin in Hypertensive Patients Who Have Average or Lower-Than-Average Cholesterol Concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): A Multicentre Randomised Controlled Trial,” <i>Lancet</i>, 2003, 361(9364):1149-58.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvastatin-pediatric-drug-information/abstract-text/12686036/pubmed" id="12686036" target="_blank">12686036</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7566020">
<a name="7566020"></a>Shepherd J, Cobbe SM, Ford I, et al, “Prevention of Coronary Heart Disease With Pravastatin in Men With Hypercholesterolemia. West of Scotland Coronary Prevention Study Group,” <i>N Engl J Med</i>, 1995, 333(20):1301-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvastatin-pediatric-drug-information/abstract-text/7566020/pubmed" id="7566020" target="_blank">7566020</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14696880">
<a name="14696880"></a>Smith DJ, Olive KE. Chinese red rice-induced myopathy. <i>South Med J</i>. 2003;96(12):1265-1267.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvastatin-pediatric-drug-information/abstract-text/14696880/pubmed" id="14696880" target="_blank">14696880</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24323134">
<a name="24323134"></a>Tonelli M, Wanner C; for the Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members. Lipid Management in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2013 Clinical Practice Guideline [published online ahead of print]. <i>Ann Intern Med</i>. 2013.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvastatin-pediatric-drug-information/abstract-text/24323134/pubmed" id="24323134" target="_blank">24323134</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12394230">
<a name="12394230"></a>Tysk C, Al-Eryani AY, Shawabkeh AA. Acute pancreatitis induced by fluvastatin therapy. <i>J Clin Gastroenterol</i>. 2002;35(5):406-408. doi:10.1097/00004836-200211000-00010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvastatin-pediatric-drug-information/abstract-text/12394230/pubmed" id="12394230" target="_blank">12394230</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17062478">
<a name="17062478"></a>van der Graaf A, Nierman MC, Firth JC, et al, "Efficacy and Safety of Fluvastatin in Children and Adolescents With Heterozygous Familial Hypercholesterolaemia," <i>Acta Paediatr</i>, 2006, 95(11):1461-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvastatin-pediatric-drug-information/abstract-text/17062478/pubmed" id="17062478" target="_blank">17062478</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34601188">
<a name="34601188"></a>Vahedian-Azimi A, Bianconi V, Makvandi S, et al. A systematic review and meta-analysis on the effects of statins on pregnancy outcomes. <i>Atherosclerosis</i>. 2021b;336:1-11. doi:10.1016/j.atherosclerosis.2021.09.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvastatin-pediatric-drug-information/abstract-text/34601188/pubmed" id="34601188" target="_blank">34601188</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34044205">
<a name="34044205"></a>Vahedian-Azimi A, Makvandi S, Banach M, Reiner Ž, Sahebkar A. Fetal toxicity associated with statins: a systematic review and meta-analysis. <i>Atherosclerosis</i>. 2021a;327:59-67. doi:10.1016/j.atherosclerosis.2021.05.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvastatin-pediatric-drug-information/abstract-text/34044205/pubmed" id="34044205" target="_blank">34044205</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 13044 Version 291.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
